Entering text into the input field will update the search result below

FDA clears Impax Labs' ANDA for generic ADHD med

Feb. 17, 2016 11:02 AM ETAmneal Pharmaceuticals, Inc. (AMRX) StockBy: Douglas W. House, SA News Editor1 Comment
  • The FDA approves Impax Laboratories' (IPXL +12.9%) abbreviated New Drug Application (ANDA) for attention deficit hyperactivity disorder (ADHD) med dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate (mixed salts of a single-entity amphetamine product) extended-release capsules in range of strengths.
  • The company plans to transition to the ANDA product from the current generic Adderall XR.
  • U.S. annual sales of branded and generic mixed amphetamines are $1.8B.

Recommended For You

About AMRX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
AMRX--
Amneal Pharmaceuticals, Inc.